CU Logo University of Colorado Anschutz Medical Campus

Research Studies

Back to Results

S0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III-Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES). Amendment 3 7.15.18

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Prevention

Scope

National

Locations

Cherry Creek Medical Center
Memorial Hospital Central
University of Colorado Hospital

Principal Investigator
Photograph of Martin Mccarter, MD

Martin Mccarter, MD

Study ID

Protocol Number: 15-1590

More information available at ClinicalTrials.gov: NCT01349881

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers